PARP1 and cancer: Venadaparib shows high PARP‐1/2 selectivity over other PARP family members and exhibits strong PARP‐trapping activity at the DNA single‐strand cleavage site, thereby effectively inhibiting the mechanism of cancer cell DNA damage recovery [19].